Table 4 Expression of ITGB1 in various cancers
From: Integrinβ-1 in disorders and cancers: molecular mechanisms and therapeutic targets
Cancer type | mRNA/Protein | High/low expression | Percentage | Clinical characteristics | Ref |
|---|---|---|---|---|---|
Gastric carcinoma (GC) | Pro | High | 82.50% (n = 160) | Lauren’s classification, differentiation degree, TNM stage | [36] |
Pro | High | Positively correlated with advanced tumor node metastases (TNM) stage and in lymphatic metastasis, but not with sex or age | [39] | ||
Pro | High | Elevated expression of ITGB1 in chemo-resistant (CR) tumor tissues | [88] | ||
Hepatocellular carcinoma (HCC) | Pro | High | 72.5% (n = 117) | [62] | |
Colorectal carcinoma (CRC) | Pro | High | 48.7% (n = 66) | Significantly associated with poor prognosis | [53] |
Pro | High | Correlated with tumor recurrence | [90] | ||
Breast cancer (BC) | Pro | High | 62% (n = 108) | Associated with shorter overall survival | [54] |
Prostate cancer (PC) | Pro | High | [45] | ||
Melanoma | Pro | High | 52% (n = 111) | With lymph node involvement | [96] |
Lung cancer (LC) | Pro | High | 38.0% (n = 50) | [97] |